Adage Capital Partners GP L.L.C. Has $1.03 Million Stake in Surrozen, Inc. $SRZN

Adage Capital Partners GP L.L.C. increased its holdings in shares of Surrozen, Inc. (NASDAQ:SRZN - Free Report) by 37.1% in the first quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 88,653 shares of the company's stock after purchasing an additional 24,000 shares during the quarter. Adage Capital Partners GP L.L.C. owned 2.70% of Surrozen worth $1,034,000 as of its most recent filing with the SEC.

A number of other large investors have also bought and sold shares of SRZN. RA Capital Management L.P. increased its stake in Surrozen by 140.3% during the 1st quarter. RA Capital Management L.P. now owns 679,130 shares of the company's stock worth $7,919,000 after purchasing an additional 396,550 shares in the last quarter. Vivo Capital LLC bought a new stake in Surrozen during the 1st quarter worth approximately $3,032,000. Driehaus Capital Management LLC bought a new position in shares of Surrozen during the 1st quarter worth approximately $2,390,000. Stempoint Capital LP grew its stake in shares of Surrozen by 91.7% during the 4th quarter. Stempoint Capital LP now owns 350,573 shares of the company's stock worth $5,031,000 after acquiring an additional 167,655 shares in the last quarter. Finally, Stonepine Capital Management LLC raised its holdings in shares of Surrozen by 108.3% in the first quarter. Stonepine Capital Management LLC now owns 285,782 shares of the company's stock valued at $3,332,000 after purchasing an additional 148,582 shares during the last quarter. 66.57% of the stock is owned by institutional investors.

Surrozen Trading Up 1.4%

Shares of NASDAQ SRZN traded up $0.16 during midday trading on Friday, reaching $11.57. The company's stock had a trading volume of 1,701 shares, compared to its average volume of 12,144. Surrozen, Inc. has a fifty-two week low of $5.90 and a fifty-two week high of $18.17. The stock has a market capitalization of $99.15 million, a price-to-earnings ratio of -0.80 and a beta of 0.62. The stock has a 50 day simple moving average of $10.27 and a 200-day simple moving average of $9.90.

Surrozen (NASDAQ:SRZN - Get Free Report) last posted its quarterly earnings data on Friday, August 8th. The company reported ($1.14) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($1.23) by $0.09. Surrozen had a negative net margin of 274.42% and a negative return on equity of 545.43%. The company had revenue of $0.98 million for the quarter. As a group, equities analysts anticipate that Surrozen, Inc. will post -8.49 EPS for the current year.

Surrozen Profile

Surrozen, Inc, a clinical stage biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair. The company is developing antibody-based therapeutics which targets various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system.